Since the new year began, Rainbow Coral Corp. (OTCBB: RBCC) has wasted no time in searching for new targets to add to its portfolio of projects for commercialization. Last week, the Company’s executive leadership accepted an invitation to tour a genome-mapping facility in Houston with which RBCC could soon partner.
New healthcare innovations related to the human genome represent a target-rich area of interest for RBCC. The Texas company currently being reviewed performs tests to identify genetic markers in patients that can potentially boost or nullify the effects of certain medications.
Such testing could dramatically change the way medications are prescribed, potentially fostering a significant reduction in global health care costs.
“Knowing specifics about an individual’s genetic make-up can greatly assist a patient’s doctor in determining correct doses of medications as well as ruling out medications that could prove harmful,” said RBCC CEO Patrick Brown. “Genome mapping opens up a host of new possibilities for doctors and patients alike, and we’re very interested in the technology’s economic potential.”
As the company searches for its next partner, RBCC’s biotech subsidiary Rainbow Biosciences remains close to a joint venture deal with Amarantus Bioscience, makers of exciting new diagnostic tools and therapies for neurological diseases such as Parkinson’s.
Amarantus recently announced highly promising results in new animal trials of its forthcoming Parkinson’s therapeutic, known as MANF.
For more information on RBCC and its biotechnology targets, please visit www.rainbowbiosciences.com/investors.
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC) and Abbott Laboratories (NYSE: ABT).
Follow us on Twitter at www.twitter.com/RBCCinfo.
About Rainbow BioSciences
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at www.rainbowbiosciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.